Targets › CSPG4
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.
Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. (UniProt, Q6UVK1)
Open in Phaseline: the race on CSPG4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Biotech | EB-DTKN-401 Dual-target CSPG4/GD2 CAR-NK cells | CSPG4, GD2 | Phase 1 | Unresectable Melanoma | Jun 2027 |
Unresectable Melanoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.